Psoriasis prevalence in the United States in a commercial insurance claims database: 2011-2017 - 11/12/19
Doi : 10.1016/j.jaad.2019.05.092
Jeffrey M. Cohen, MD, Priscilla W. Wong, MS, David E. Cohen, MD, MPH, Randie H. Kim, MD, PhD ⁎ 
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York
∗Correspondence to: Randie H. Kim, MD, PhD, The Ronald O. Perelman Department of Dermatology, NYU School of Medicine, 240 E 38th St, 11th Floor, New York, NY 10016.The Ronald O. Perelman Department of DermatologyNYU School of Medicine240 E 38th St, 11th FloorNew YorkNY10016
Abbreviation used : CI
| Funding sources: None. |
|
| Disclosure: Dr D. Cohen has been a consultant for and received honoraria from Dermavent, Ferndale Laboratories, Medimetriks, Cutanea, Ferrer, Celgene, and FIDE (FIDE receives industry sponsorship from AbbVie, Almirall, Bausch and Lomb, Bristol Myers, Celgene, Dermavant, Dermira, Janssen, Kyowa Hakko Kirin, LEO, Lilly, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, Sun Pharma, UCB, and Valeant); has stock or stock options with Dermira, Medimetriks, Brickell Biotech, and Kadmon; and serves on the board of directors of Dermira and Kadmon. Dr J. Cohen, Ms Wong, and Dr Kim have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 82 - N° 1
P. 229-230 - janvier 2020 Retour au numéro
Article précédent
- The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis
- Taylor E. Woo, Christopher D. Sibley
- Characterizing dupilumab facial redness: A multi-institution retrospective medical record review
- Reid A. Waldman, Madeline E. DeWane, Brett Sloan, Jane M. Grant-Kels
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?